Source comparison
Tesamorelin Acetate Same as Tesamorelin: Supplier Comparison
Research-grade peptide supplier (503B-registered) 'Tesamorelin Acetate' 5255 Da (with acetate) HPLC ≥98%, mass spec confirmation Explicitly stated on CoA Excellent. Full traceability Generic peptide vendor (non-503B) 'Tesamorelin' 5136 Da (peptide only) HPLC c
This comparison does not assign a generated winner or score.
- Research-grade peptide supplier (503B-registered)
- 'Tesamorelin Acetate'
- 5255 Da (with acetate)
- HPLC ≥98%, mass spec confirmation
- Explicitly stated on CoA
- Excellent. Full traceability
- Generic peptide vendor (non-503B)
- 'Tesamorelin'
- 5136 Da (peptide only)
- HPLC claimed, no third-party verification
- Rarely clarified
- Moderate. Dosing ambiguity possible
- Clinical formulation (FDA-approved, e.g., Egrifta)
- 'Tesamorelin (as acetate)'
- Not disclosed on patient labeling
- Full GMP batch testing
- Implicit in formulation notes
- N/A for research. Pre-constituted
- International supplier (non-US)
- Variable. 'Tesamorelin HCl' or 'Tesamorelin Acetate'
- Often omitted or incorrect
- Inconsistent. CoA quality varies widely
- Rarely addressed
- Poor. Counterion substitution risk
- Real Peptides
- 5255 Da (acetate salt specified)
- Third-party HPLC + mass spec on every batch
- Clearly noted on CoA with net peptide content
- Excellent. Lab-grade reliability